Company intelligence / Profile preview
Shionogi & Co., Ltd.
Osaka, Osaka Prefecture, Japanshionogi.com ↗
- Ownership
- Public · 4507
- Employees
- ~6082
- Development stage
- Other
01
Overview
Shionogi has multiple approved products including Crestor, Fetroja/Fetcroja (cefiderocol), and several pipeline candidates in various stages of development across infectious diseases, rare diseases, and other therapeutic areas.
- Therapeutic areas
- PulmonologyMetabolic DisordersEndocrinologyOncologyRare DiseasesNeurologyInfectious Diseases
- Modalities
- Small moleculesantibodiesvaccines
- Industry
- Biotech
02
Drug pipeline
89 assets88 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $16B
- Total revenue
- $3.2B
- Enterprise value
- $18B
Beyond the preview
Go deeper on Shionogi & Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shionogi & Co., Ltd..